{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:09:26Z","timestamp":1792069766794,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","jada.ada.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of the American Dental Association"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.adaj.2019.03.006","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T04:59:25Z","timestamp":1561697965000},"page":"664-675.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy"],"prefix":"10.1016","volume":"150","author":[{"given":"Mohamed E.","family":"Awad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Jernigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Elsalanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.adaj.2019.03.006_bib1","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"10","key":"10.1016\/j.adaj.2019.03.006_bib2","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"3","key":"10.1016\/j.adaj.2019.03.006_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1747-4477.2009.00213.x","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw: 2009 update","volume":"35","author":"Ruggiero","year":"2009","journal-title":"Aust Endod J"},{"issue":"3","key":"10.1016\/j.adaj.2019.03.006_bib4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.joms.2008.09.031","article-title":"Sinus tracts: an early sign of bisphosphonate-associated osteonecrosis of the jaws?","volume":"67","author":"Mawardi","year":"2009","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"8","key":"10.1016\/j.adaj.2019.03.006_bib5","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/jbmr.2888","article-title":"A\u00a0crisis in the treatment of osteoporosis","volume":"31","author":"Khosla","year":"2016","journal-title":"J\u00a0Bone Miner Res"},{"issue":"7","key":"10.1016\/j.adaj.2019.03.006_bib6","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.joms.2010.02.037","article-title":"Oral bisphosphonate-associated osteonecrosis of the jaw after implant surgery: a case report and literature review","volume":"68","author":"Bedogni","year":"2010","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"1","key":"10.1016\/j.adaj.2019.03.006_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1348-8643(12)00045-6","article-title":"Pathophysiology of BRONJ: drug-related osteoclastic disease of the jaw","volume":"10","author":"Ikebe","year":"2013","journal-title":"Oral Sci Int"},{"issue":"2","key":"10.1016\/j.adaj.2019.03.006_bib8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","article-title":"Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure","volume":"68","author":"Lo","year":"2010","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"3","key":"10.1016\/j.adaj.2019.03.006_bib9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"6","key":"10.1016\/j.adaj.2019.03.006_bib10","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.adaj.2019.03.006_bib11","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research [editorial]","volume":"22","author":"Khosla","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"issue":"22","key":"10.1016\/j.adaj.2019.03.006_bib12","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","article-title":"Osteonecrosis of the jaw: do bisphosphonates pose a risk?","volume":"355","author":"Bilezikian","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"18 suppl","key":"10.1016\/j.adaj.2019.03.006_bib13","article-title":"Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy [abstract 8528]","volume":"24","author":"Hoff","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.adaj.2019.03.006_bib14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.adaj.2019.03.006_bib15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.joms.2007.11.032","article-title":"Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study","volume":"66","author":"Wessel","year":"2008","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"9","key":"10.1016\/j.adaj.2019.03.006_bib16","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0278-2391(03)00328-8","article-title":"Osteonecrosis of the jaws associated with cancer chemotherapy","volume":"61","author":"Wang","year":"2003","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.adaj.2019.03.006_bib17","doi-asserted-by":"crossref","first-page":"654027","DOI":"10.5402\/2011\/654027","article-title":"Osteoporosis and bisphosphonate-related osteonecrosis of the jaw bone","volume":"2011","author":"Villa","year":"2011","journal-title":"ISRN Rheumatol"},{"issue":"1","key":"10.1016\/j.adaj.2019.03.006_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1634\/theoncologist.2010-0183","article-title":"Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw","volume":"16","author":"Miksad","year":"2011","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.adaj.2019.03.006_bib19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jcms.2011.04.011","article-title":"Awareness and education of patients receiving bisphosphonates","volume":"40","author":"Bauer","year":"2012","journal-title":"J\u00a0Craniomaxillofac Surg"},{"issue":"4","key":"10.1016\/j.adaj.2019.03.006_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bjoms.2010.05.007","article-title":"Bisphosphonate osteonecrosis of the jaw: a literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention","volume":"49","author":"Patel","year":"2011","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"9","key":"10.1016\/j.adaj.2019.03.006_bib21","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.jcms.2015.07.035","article-title":"Surgical treatment of bisphosphonate-associated osteonecrosis: prognostic score and long-term results","volume":"43","author":"Reich","year":"2015","journal-title":"J\u00a0Craniomaxillofac Surg"},{"issue":"3","key":"10.1016\/j.adaj.2019.03.006_bib22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","year":"2007","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"2","key":"10.1016\/j.adaj.2019.03.006_bib23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/PL00005830","article-title":"Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy","volume":"66","author":"Rosen","year":"2000","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"10.1016\/j.adaj.2019.03.006_bib24","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.joms.2008.01.054","article-title":"Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"66","author":"Khosla","year":"2008","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"12","key":"10.1016\/j.adaj.2019.03.006_bib25","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"65","author":"Marx","year":"2007","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"4","key":"10.1016\/j.adaj.2019.03.006_bib26","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.adaj.2019.03.006_bib27","series-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011)","year":"2011"},{"issue":"9","key":"10.1016\/j.adaj.2019.03.006_bib28","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"issue":"8","key":"10.1016\/j.adaj.2019.03.006_bib29","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jclinepi.2009.10.002","article-title":"The development of a quality appraisal tool for studies of diagnostic reliability (QAREL)","volume":"63","author":"Lucas","year":"2010","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"11","key":"10.1016\/j.adaj.2019.03.006_bib30","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.oraloncology.2008.01.012","article-title":"Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates","volume":"44","author":"Bagan","year":"2008","journal-title":"Oral Oncol"},{"issue":"1","key":"10.1016\/j.adaj.2019.03.006_bib31","first-page":"31","article-title":"Surgical protocol in patients at risk for bisphosphonate osteonecrosis of the jaws: clinical use of serum telopetide CTX in preventive monitoring of surgical risk","volume":"3","author":"Carini","year":"2012","journal-title":"Ann Stomatol (Roma)"},{"issue":"8","key":"10.1016\/j.adaj.2019.03.006_bib32","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.joms.2014.02.036","article-title":"A\u00a0C-terminal crosslinking telopeptide test-based protocol for patients on oral bisphosphonates requiring extraction: a prospective single-center controlled study","volume":"72","author":"Hutcheson","year":"2014","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"9","key":"10.1016\/j.adaj.2019.03.006_bib33","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.joms.2010.05.043","article-title":"Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates","volume":"68","author":"Lazarovici","year":"2010","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"1","key":"10.1016\/j.adaj.2019.03.006_bib34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/ID.0b013e3181cec8bc","article-title":"CTX biochemical marker of bone\u00a0metabolism: is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? part II: a\u00a0prospective clinical study","volume":"19","author":"Lee","year":"2010","journal-title":"Implant Dent"},{"issue":"4","key":"10.1016\/j.adaj.2019.03.006_bib35","first-page":"406","article-title":"Assessing the association between bisphosphonate exposure and delayed mucosal healing after tooth extraction","volume":"144","author":"Migliorati","year":"2013","journal-title":"JADA"},{"issue":"2","key":"10.1016\/j.adaj.2019.03.006_bib36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11845-011-0790-5","article-title":"A\u00a0role for C-terminal cross-linking telopeptide (CTX) level to predict the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) following oral surgery?","volume":"181","author":"O'Connell","year":"2012","journal-title":"Ir J Med Sci"},{"issue":"4","key":"10.1016\/j.adaj.2019.03.006_bib37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.tripleo.2010.04.023","article-title":"Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers","volume":"110","author":"Fleisher","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"12","key":"10.1016\/j.adaj.2019.03.006_bib38","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/j.joms.2009.04.067","article-title":"Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws","volume":"67","author":"Kwon","year":"2009","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"12","key":"10.1016\/j.adaj.2019.03.006_bib39","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/hed.23235","article-title":"Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: a 4-year cohort study","volume":"35","author":"Lee","year":"2013","journal-title":"Head Neck"},{"issue":"2","key":"10.1016\/j.adaj.2019.03.006_bib40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ajoms.2012.06.007","article-title":"Bone turnover and inflammatory markers of bisphosphonate-related osteonecrosis of the jaw in female osteoporosis patients","volume":"25","author":"Choi","year":"2013","journal-title":"J\u00a0Oral Maxillofac Surg Med Pathol"},{"issue":"1","key":"10.1016\/j.adaj.2019.03.006_bib41","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bone.2013.08.005","article-title":"Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates","volume":"57","author":"Kim","year":"2013","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.adaj.2019.03.006_bib42","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.joms.2009.02.004","article-title":"Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws","volume":"67","author":"Kunchur","year":"2009","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"2","key":"10.1016\/j.adaj.2019.03.006_bib43","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1097\/SCS.0000000000004224","article-title":"Cross-sectional study of four serological bone turnover markers for the risk assessment of medication-related osteonecrosis of the jaw","volume":"29","author":"Peisker","year":"2018","journal-title":"J\u00a0Craniofac Surg"},{"issue":"4","key":"10.1016\/j.adaj.2019.03.006_bib44","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.joms.2015.09.028","article-title":"Serum markers of bone turnover and angiogenesis in patients with bisphosphonate-related osteonecrosis of the jaw after discontinuation of long-term intravenous bisphosphonate therapy","volume":"74","author":"Thumbigere-Math","year":"2016","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"6","key":"10.1016\/j.adaj.2019.03.006_bib45","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s10103-011-0974-2","article-title":"Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery?","volume":"26","author":"Atalay","year":"2011","journal-title":"Lasers Med Sci"},{"issue":"3","key":"10.1016\/j.adaj.2019.03.006_bib46","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.4317\/medoral.17583","article-title":"Study of serum CTX in 50 oral surgical patients","volume":"17","author":"Flichy-Fern\u00e1ndez","year":"2012","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"2","key":"10.1016\/j.adaj.2019.03.006_bib48","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1373\/clinchem.2016.259085","article-title":"Bone turnover markers in the diagnosis and monitoring of metabolic bone disease","volume":"63","author":"Greenblatt","year":"2017","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.adaj.2019.03.006_bib49","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.joms.2014.10.034","article-title":"Bisphosphonate therapy: C-terminal telopeptide testing facilitates devising more accurate consent for extraction","volume":"73","author":"Friedlander","year":"2015","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"9","key":"10.1016\/j.adaj.2019.03.006_bib50","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.joms.2015.03.015","article-title":"High C-terminal cross-linking telopeptide levels are associated with a minimal risk of osteonecrosis of the jaws in patients taking oral bisphosphonates and having exodontia","volume":"73","author":"Friedlander","year":"2015","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"suppl 1","key":"10.1016\/j.adaj.2019.03.006_bib51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0305-7372(06)80003-4","article-title":"Bone markers and current laboratory assays","volume":"32","author":"Hannon","year":"2006","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.adaj.2019.03.006_bib52","first-page":"1243","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs","volume":"142","author":"Hellstein","year":"2011","journal-title":"JADA"},{"issue":"10","key":"10.1016\/j.adaj.2019.03.006_bib53","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00228-006-0174-3","article-title":"An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice","volume":"62","author":"Leeming","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.adaj.2019.03.006_bib54","article-title":"Assessing the utility of serum C-telopeptide cross-link of type 1 collagen as a predictor of bisphosphonate-related osteonecrosis of the jaw: a systematic review and meta-analysis","volume":"147","author":"Enciso","year":"2016","journal-title":"JADA"},{"issue":"2","key":"10.1016\/j.adaj.2019.03.006_bib55","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrrheum.2011.181","article-title":"Epidemiology and pathogenesis of osteonecrosis of the jaw","volume":"8","author":"Reid","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.adaj.2019.03.006_bib56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bone.2018.01.030","article-title":"Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function","volume":"110","author":"Elsayed","year":"2018","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.adaj.2019.03.006_bib57","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1359\/jbmr.090203","article-title":"Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw","volume":"24","author":"Baim","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.adaj.2019.03.006_bib58","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.oooo.2017.07.011","article-title":"AAOM clinical practice statement: subject\u2014the use of serum C-terminal telopeptide cross-link of type 1 collagen (CTX) testing in predicting risk of osteonecrosis of the jaw (ONJ)","volume":"124","year":"2017","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"2","key":"10.1016\/j.adaj.2019.03.006_bib59","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1017\/S0266462312000086","article-title":"The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies","volume":"28","author":"Morrison","year":"2012","journal-title":"Int J Technol Assess Health Care"},{"issue":"8","key":"10.1016\/j.adaj.2019.03.006_bib60","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jclinepi.2004.08.021","article-title":"Language of publication restrictions in systematic reviews gave different results depending on whether the intervention was conventional or complementary","volume":"58","author":"Pham","year":"2005","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.adaj.2019.03.006_bib61","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1155\/2018\/2684924","article-title":"The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention","volume":"2018","author":"Di Fede","year":"2018","journal-title":"Biomed Res Int"}],"container-title":["The Journal of the American Dental Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002817719302119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002817719302119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T04:08:07Z","timestamp":1757563687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002817719302119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0002817719302119"],"URL":"https:\/\/doi.org\/10.1016\/j.adaj.2019.03.006","relation":{},"ISSN":["0002-8177"],"issn-type":[{"value":"0002-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy","name":"articletitle","label":"Article Title"},{"value":"The Journal of the American Dental Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adaj.2019.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Dental Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}